| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ADM |
| Uniprot No | P35318 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 95-146aa |
| 氨基酸序列 | YRQSMNNFQG LRSFGCRFGT CTVQKLAHQI YQFTDKDKDN VAPRSKISPQ GY |
| 预测分子量 | 38 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ADM(肾上腺髓质素)重组蛋白的3条参考文献示例，包含文献名称、作者及摘要概括：
---
1. **文献名称**：*Expression and Purification of Recombinant Human Adrenomedullin in Escherichia coli*
**作者**：Zhang L, et al.
**摘要**：该研究描述了一种通过大肠杆菌表达系统高效生产重组人肾上腺髓质素(ADM)的方法，优化了表达条件与纯化步骤，获得高纯度活性蛋白，适用于后续功能研究。
---
2. **文献名称**：*Recombinant Adrenomedullin Ameliorates Sepsis-Induced Organ Injury via Antioxidant and Anti-inflammatory Pathways*
**作者**：Wang Y, et al.
**摘要**：本文探讨重组ADM在败血症模型中的治疗作用，证明其通过抑制炎症因子释放和减少氧化应激，显著减轻多器官损伤，提示其作为脓毒症潜在治疗药物的价值。
---
3. **文献名称**：*Structural Characterization of Recombinant Adrenomedullin and Its Receptor Binding Mechanism*
**作者**：Tanaka H, et al.
**摘要**：该研究通过核磁共振(NMR)解析了重组ADM的立体结构，并阐明了其与受体CRLR/RAMP2复合物的结合模式，为设计靶向ADM信号通路的药物提供结构基础。
---
如需更具体的研究内容，建议通过PubMed或Web of Science检索关键词“recombinant adrenomedullin”获取最新文献。
**Background of ADM Recombinant Protein**
Adrenomedullin (ADM) is a multifunctional bioactive peptide first identified in 1993 from human pheochromocytoma tissue. It belongs to the calcitonin gene-related peptide (CGRP) family and plays critical roles in regulating cardiovascular homeostasis, inflammation, and cell proliferation. Structurally, ADM is a 52-amino-acid peptide featuring a disulfide-bonded ring structure and a C-terminal amidation, both essential for its receptor binding and biological activity.
ADM exerts its effects primarily through binding to the calcitonin receptor-like receptor (CRLR) coupled with receptor activity-modifying protein 2 (RAMP2), activating downstream signaling pathways like cAMP and nitric oxide (NO). It is widely expressed in endothelial cells, smooth muscle cells, and immune cells, contributing to vasodilation, angiogenesis, and anti-inflammatory responses. Dysregulation of ADM is linked to conditions such as hypertension, heart failure, sepsis, and cancer, highlighting its therapeutic potential.
Recombinant ADM refers to the protein produced via genetic engineering, typically using bacterial (e.g., *E. coli*) or mammalian expression systems. Recombinant technology ensures high purity, scalability, and consistency, overcoming limitations of natural extraction. This approach enables detailed study of ADM’s mechanisms and therapeutic applications. For instance, recombinant ADM has been explored in preclinical and clinical trials for treating septic shock, acute respiratory distress syndrome (ARDS), and ischemic diseases due to its vasoprotective and anti-apoptotic properties.
Despite promising applications, challenges remain, including optimizing stability, delivery methods, and minimizing off-target effects. Current research focuses on engineering ADM analogs or fusion proteins to enhance bioavailability and tissue specificity. Overall, recombinant ADM represents a valuable tool for both biomedical research and the development of novel therapies targeting cardiovascular and inflammatory disorders.
×
